CDXS vs TMO
CDXS: Codexis uses its proprietary directed evolution technology to engineer enzymes that improve the manufacturing efficiency and sustainability of small molecule drugs and complex RNA therapeutics. TMO: A massive, diversified life sciences conglomerate providing the essential infrastructure, tools, and services that enable scientific research and global healthcare diagnostics.
Side-by-side fundamentals
| Metric | CDXS | TMO | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $1.36 | $651.98 | |
| Market cap | $149M | $241.1B | |
| P/E as of 2026-10-08 | n/a | 35.10 | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | n/a | 169.13 | |
| Net margin FY2025, SEC XBRL | -62.5% | +15.0% | TMO higher |
| Operating margin FY2025, SEC XBRL | -59.3% | +17.4% | TMO higher |
| ROE FY2025, SEC XBRL | -87.0% | +12.6% | TMO higher |
| ROA FY2025, SEC XBRL | -29.8% | +6.1% | TMO higher |
| Debt / equity as of 2026-09-03 | 1.24 | 0.81 | TMO lower |
| Revenue growth (YoY) as of 2026-09-03 | +35.9% | +7.2% | CDXS higher |
| Revenue CAGR (3y) SEC XBRL | -20.2% | -0.3% | TMO higher |
| Dividend yield as of 2026-09-02 | n/a | +0.3% | |
| Dividend streak (yrs) SEC XBRL | 0 | 14 | TMO higher |
| Beta as of 2026-09-03 | 1.80 | 0.77 | |
| 1-year return as of 2026-10-08 close | -48.7% | +21.6% | TMO higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.